Literature DB >> 17602070

ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial.

Jean-Charles Soria.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17602070     DOI： 10.1200/JCO.2007.11.3167

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  On Bayesian methods of exploring qualitative interactions for targeted treatment.

Authors:  Wei Chen; Debashis Ghosh; Trivellore E Raghunathan; Maxim Norkin; Daniel J Sargent; Gerold Bepler
Journal:  Stat Med       Date:  2012-06-26       Impact factor: 2.373

2.  A non-cross-linking platinum-acridine agent with potent activity in non-small-cell lung cancer.

Authors:  Zhidong Ma; Jayati Roy Choudhury; Marcus W Wright; Cynthia S Day; Gilda Saluta; Gregory L Kucera; Ulrich Bierbach
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

3.  Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.

Authors:  Eszter Podmaniczky; Katalin Fábián; Judit Pápay; Rita Puskás; Márton Gyulai; József Furák; László Tiszlavicz; György Losonczy; József Tímár; Judit Moldvay
Journal:  Pathol Oncol Res       Date:  2014-09-07       Impact factor: 3.201

4.  Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.

Authors:  Jeffrey G Schneider; Nosha Farhadfar; Abirami Sivapiragasam; Matthew Geller; Shahidul Islam; Elena Selbs
Journal:  Oncologist       Date:  2014-04-04

5.  ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.

Authors:  Diane Allingham-Hawkins; Andrew Lea; Susan Levine
Journal:  PLoS Curr       Date:  2010-12-06

6.  Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10.

Authors:  Alex Soltermann; Sandra Kilgus-Hawelski; Silvia Behnke; Martina Storz; Holger Moch; Beata Bode
Journal:  J Clin Bioinforma       Date:  2011-09-30

7.  A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to Chemoradiotherapy.

Authors:  Atsunari Kawashima; Hitoshi Takayama; Akira Tsujimura
Journal:  Adv Urol       Date:  2011-10-26

8.  Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance.

Authors:  Weiwei Wang; Lijun Zhang; Liang Liu; Yongfa Zheng; Yong Zhang; Siyuan Yang; Rongliang Shi; Shaojia Wang
Journal:  Oncol Rep       Date:  2017-02-14       Impact factor: 3.906

9.  A method for biomarker directed survival prediction in advanced non-small-cell lung cancer patients treated with Carboplatin-based therapy.

Authors:  Wei Chen; Gerold Bepler
Journal:  J Pers Med       Date:  2013-09-01

10.  Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.

Authors:  Wendian Zhang; Hechao Zhou; Ying Yu; Jingjing Li; Haiwen Li; Danxian Jiang; Zihong Chen; Donghong Yang; Zumin Xu; Zhonghua Yu
Journal:  Onco Targets Ther       Date:  2016-06-02       Impact factor: 4.147
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.